-
Posted: August 11th, 2022, 2:00pm GMT
Conditions: Hepatobiliary Cancer; Pancreatic Cancer; Hepatocellular Carcinoma; Cholangiocarcinoma; Ampullary Cancer; Pancreatic Carcinoma
Intervention: Diagnostic Test: ctDNA Blood Collection
Sponsor: University of California, Irvine
Not yet recruiting
-
Posted: August 5th, 2022, 2:00pm GMT
Conditions: Hepatocellular Cancer; Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; Oesophageal Cancer; Stomach Cancer
Intervention:
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting
-
Posted: July 11th, 2022, 2:00pm GMT
Conditions: Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma
Interventions: Biological: Durvalumab; Drug: Gemcitabine; Drug: Nab paclitaxel; Biological: Tremelimumab; Drug: Propranolol; Drug: Cisplatin
Sponsor: AHS Cancer Control Alberta
Not yet recruiting
-
Posted: July 7th, 2022, 2:00pm GMT
Condition: Extrahepatic Cholangiocarcinoma
Intervention: Drug: Toripalimab, Gemcitabine,Oxaliplatin
Sponsor: Xuhua Duan
Recruiting
-
Posted: June 24th, 2022, 2:00pm GMT
Condition: Perihilar Cholangiocarcinoma
Intervention: Drug: PD-1antibody plus GEMOX
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting
-
Posted: June 23rd, 2022, 2:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: SMT-NK inj.+Pembrolizumab; Drug: Pembrolizumab
Sponsor: SMT bio Co., Ltd.
Recruiting
-
Posted: June 16th, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Induction Chemotherapy Triplet Therapy; Radiation: Concurrent Y-90 treatment; Drug: Consolidation Doublet Therapy:
Sponsor: Inova Health Care Services
Not yet recruiting
-
Posted: June 14th, 2022, 2:00pm GMT
Conditions: Inoperable Disease; Bile Duct Cancer
Intervention: Procedure: Endoscopic ultrasound with fine needle biopsy
Sponsor: Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Recruiting
-
Posted: June 9th, 2022, 2:00pm GMT
Conditions: Gastrointestinal Cancer; Cholangiocarcinoma; Liver Cancer; Colorectal Adenocarcinoma; Pancreatic Cancer; Gastric Cancer
Intervention: Drug: ARB202
Sponsor: Arbele Pty Ltd
Recruiting
-
Posted: June 3rd, 2022, 2:00pm GMT
Conditions: Incidence of Cholangiocarcinoma on Choledochal Cysts; Postoperative Complications in Choledochal Cysts; Choledochal Cyst Monitoring
Intervention:
Sponsor: María Teresa Moreno Asencio
Recruiting
-
Posted: June 2nd, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Binkui Li
Recruiting
-
Posted: May 27th, 2022, 2:00pm GMT
Conditions: Common Bile Duct Stricture; Jaundice; Malignant
Intervention:
Sponsor: Azienda Unità Sanitaria Locale della Romagna
Recruiting
-
Posted: April 27th, 2022, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: HAIC combined with donafenib and sintilimab
Sponsor: Zhongda Hospital
Not yet recruiting
-
Posted: April 22nd, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Toripalimab; Drug: Lenvatinib mesylate capsules; Drug: Placebo IV; Drug: Oral placebo; Drug: Oxaliplatin for injection; Drug: Gemcitabine hydrochloride; Drug: Cisplatin
Sponsor: Shanghai Junshi Bioscience Co., Ltd.
Not yet recruiting
-
Posted: April 14th, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention:
Sponsors: Qilu Hospital of Shandong University; Jinan Central Hospital; Shandong Provincial Hospital; Jinan Military General Hospital
Recruiting
-
Posted: April 14th, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Perflutren Protein-Type A Microspheres; Procedure: Contrast-Enhanced Ultrasound
Sponsor: Thomas Jefferson University
Recruiting
-
Posted: April 13th, 2022, 2:00pm GMT
Condition: Solid Tumors
Intervention: Drug: Bemarituzumab
Sponsor: Amgen
Not yet recruiting
-
Posted: April 11th, 2022, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver Fluke-Related Cholangiocarcinoma; Opisthorchiasis
Intervention: Behavioral: eCHEC program
Sponsors: McMaster University; Khon Kaen University; Global Alliance for Chronic Diseases (GACD); Canadian Institutes of Health Research (CIHR)
Not yet recruiting
-
Posted: April 6th, 2022, 2:00pm GMT
Conditions: CNS Cancer; Head and Neck Cancer; GI Cancer; Gynecologic Cancer; Prostate Cancer; Thoracic Cancer; Breast Cancer
Intervention: Radiation: Pencil Beam Scanning Proton Therapy
Sponsor: The New York Proton Center
Recruiting
-
Posted: April 5th, 2022, 2:00pm GMT
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non Small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Cancer; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM438; Drug: Pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting
-
Posted: March 23rd, 2022, 2:00pm GMT
Conditions: Primary Liver Cancer; Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Combined Hepatocellular-cholangiocarcinoma
Intervention: Other: Observation
Sponsors: Geneplus-Beijing Co. Ltd.; Eastern Hepatobiliary Surgery Hospital
Recruiting
-
Posted: March 23rd, 2022, 2:00pm GMT
Condition: Post Operative Pancreatic Fistula
Intervention: Other: no intervention
Sponsor: Institute of Liver and Biliary Sciences, India
Recruiting
-
Posted: March 23rd, 2022, 2:00pm GMT
Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Intervention: Biological: Neoantigen specific TCR-T cell drug product
Sponsor: Alaunos Therapeutics
Not yet recruiting
-
Posted: March 22nd, 2022, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: HAIC Combined with Tislelizumab and Apatinib
Sponsor: Yunfei Yuan
Recruiting
-
Posted: March 18th, 2022, 2:00pm GMT
Conditions: Metastatic Colorectal Cancer (Mcrc); Intrahepatic Cholangiocarcinoma (Icc); Colorectal Cancer; Colorectal Neoplasms; Cholangiocarcinoma; Intrahepatic Bile Duct Cancer; Bile Duct Cancer; Bile Duct Neoplasms
Interventions: Drug: Floxuridine; Drug: 5-Fluorouracil; Drug: Irinotecan; Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP); Drug: Oxaliplatin; Drug: Leucovorin; Drug: M9241; Drug: Gemcitabine; Drug: Dexamethasone
Sponsor: National Cancer Institute (NCI)
Not yet recruiting
-
Posted: March 17th, 2022, 2:00pm GMT
Conditions: Distal Bile Duct Adenocarcinoma; Gallbladder Carcinoma; Intrahepatic Cholangiocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVB Gallbladder Cancer AJCC v8
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Nab-paclitaxel; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: March 14th, 2022, 2:00pm GMT
Conditions: Peritoneal Carcinomatosis; Peritoneal Metastases; Colorectal Cancer; Small Bowel Cancer; Appendix Cancer; Gastric Cancer; Pancreatic Cancer; Bile Duct Cancer
Intervention: Drug: PIPAC with Nal-IRI
Sponsors: University Hospital, Ghent; Kom Op Tegen Kanker; University Ghent
Not yet recruiting
-
Posted: March 11th, 2022, 3:00pm GMT
Condition: Locally Advanced Solid Tumor
Intervention: Drug: TNG908
Sponsor: Tango Therapeutics, Inc.
Recruiting
-
Posted: March 4th, 2022, 3:00pm GMT
Conditions: Adverse Drug Event; Colon Cancer; Breast Cancer; Pancreas Cancer; Rectal Cancer; Gastric Cancer; Oesophageal Cancer; Bile Duct Cancer
Intervention: Genetic: DPYD genotype
Sponsors: University of Southern Denmark; Odense University Hospital
Recruiting
-
Posted: March 3rd, 2022, 3:00pm GMT
Condition: Resectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Capecitabine; Device: Selective Internal Radiotherapy (SIRT); Procedure: Surgery
Sponsor: Center Eugene Marquis
Recruiting
-
Posted: February 14th, 2022, 3:00pm GMT
Conditions: Biliary Tract Cancer (CCA); Intrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Cholangiocarcinoma; Gall Bladder Carcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab; Drug: Capecitabine
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting
-
Posted: February 4th, 2022, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma
Intervention: Drug: VG161
Sponsor: Virogin Biotech Canada Ltd
Not yet recruiting
-
Posted: January 31st, 2022, 3:00pm GMT
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Renal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma
Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting
-
Posted: January 18th, 2022, 3:00pm GMT
Conditions: Gynecologic Cancer; Colorectal Cancer; Pancreatic Cancer; Non-small Cell Lung Cancer; Cholangiocarcinoma; Ovarian Cancer; Endometrial Cancer; Ovarian Carcinoma; Ovary Neoplasm; Squamous Cell Lung Cancer; Adenocarcinoma of Lung; Adenosquamous Cell Lung Cancer
Interventions: Biological: Neoantigen specific TCR-T cell drug product; Biological: Aldesleukin (IL-2)
Sponsor: Alaunos Therapeutics
Recruiting
-
Posted: January 18th, 2022, 3:00pm GMT
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma
Intervention: Drug: SGN-B7H4V
Sponsor: Seagen Inc.
Recruiting
-
Posted: January 6th, 2022, 3:00pm GMT
Conditions: Breast Cancer; Uterine Cancer; Ovarian Cancer; Non Small Cell Lung Cancer (NSCLC); Cervical Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC), Except for Nasopharyngeal Carcinoma; Urothelial Cancer; Cholangiocarcinoma (CCA)
Intervention: Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
Sponsor: Genmab
Recruiting
-
Posted: January 4th, 2022, 3:00pm GMT
Conditions: Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor
Intervention: Drug: EMB-01
Sponsors: Shanghai EpimAb Biotherapeutics Co., Ltd.; Labcorp Drug Development, Inc.
Recruiting
-
Posted: January 3rd, 2022, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Derazantinib
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Recruiting
-
Posted: December 28th, 2021, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Lenvatinib Pill,Paclitaxel
Sponsors: National Health Research Institutes, Taiwan; National Cheng-Kung University Hospital; National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Chang Gung Memorial Hospital; China Medical University, Taiwan
Recruiting
-
Posted: December 9th, 2021, 3:00pm GMT
Condition: HER2-positive Advanced Solid Tumor
Intervention: Biological: DB-1303
Sponsor: DualityBio Inc.
Recruiting
-
Posted: November 24th, 2021, 3:00pm GMT
Condition: Immune System
Intervention: Other: blood samples
Sponsors: Centre Georges Francois Leclerc; Institut de Recherches Internationales Servier
Recruiting
-
Posted: November 18th, 2021, 3:00pm GMT
Conditions: Ovarian Cancer; Endometrial Cancer; Colo-rectal Cancer; Cholangiocarcinoma; Non-small Cell Lung Cancer; Pancreas Cancer
Intervention:
Sponsors: Alaunos Therapeutics; M.D. Anderson Cancer Center
Recruiting
-
Posted: September 22nd, 2021, 2:00pm GMT
Conditions: Liver Malignant Tumors; Cholangiocarcinoma Metastatic; Pancreatic Cancer; Melanoma
Intervention: Device: high dose rate brachytherapy
Sponsor: M.D. Anderson Cancer Center
Recruiting
-
Posted: August 11th, 2021, 2:00pm GMT
Conditions: Bile Duct Cancer; Gall Bladder Cancer; Breast Cancer; Neuroendocrine Tumors; Ovarian Cancer; Pancreatic Adenocarcinoma; Soft Tissue Sarcoma; Vulvar Cancer; Prostate Cancer
Interventions: Drug: Atezolizumab; Drug: Tivozanib
Sponsors: University of Florida; Genentech, Inc.; Aveo Oncology Pharmaceuticals
Recruiting
-
Posted: August 4th, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Drug: Novel combination of chemotherapy and immunotherapy
Sponsor: University of Alabama at Birmingham
Recruiting
-
Posted: July 21st, 2021, 2:00pm GMT
Conditions: Advanced Biliary Tract Cancer; Neuroendocrine Tumors; Female Reproductive System Neoplasm; MSI-H Solid Malignant Tumor
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting
-
Posted: July 1st, 2021, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma
Intervention:
Sponsor: University of Oxford
Recruiting
-
Posted: June 28th, 2021, 2:00pm GMT
Condition: Malignant Biliary Obstruction
Interventions: Procedure: Intraductal Radio-Frequency Ablation; Device: Biliary Stent Placement
Sponsors: University Hospitals Dorset NHS Foundation Trust; Aquilant Services; The Christie NHS Foundation Trust
Not yet recruiting
-
Posted: June 18th, 2021, 2:00pm GMT
Conditions: Metastatic Cancer; Foregut Carcinoid Tumor; Gastric Adenocarcinoma; Gallbladder Adenocarcinoma; Liver Cancer; GI Cancer; GI Carcinoma; Lung Cancer
Interventions: Drug: Standard of Care Chemotherapy; Procedure: Video-Assisted Thoracic Surgery (VATS); Procedure: Lobectomy; Radiation: Consolidative Radiation; Radiation: Ablation Treatment; Procedure: Resection or Excision; Procedure: Peritonectomy; Other: Transarterial Radioembolization
Sponsor: University of Chicago
Not yet recruiting
-
Posted: June 9th, 2021, 2:00pm GMT
Conditions: Cholangiocarcinoma; FGFR2 Fusion; FGFR2 Gene Mutation; FGFR1 Alteration; FGFR3 Alteration
Intervention: Drug: TT-00420
Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting
-
Posted: June 4th, 2021, 2:00pm GMT
Conditions: Mesothelioma; Glioblastoma; Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Pancreatic Ductal Adenocarcinoma; Gastric Cancer; Squamous Cell Carcinoma of Head and Neck; Cholangiocarcinoma; Breast Cancer; Ovarian Cancer; Cervical Cancer; Endocervical Cancer; Colorectal Cancer; Esophageal Cancer
Interventions: Drug: NGM707; Drug: NGM707 plus pembrolizumab
Sponsors: NGM Biopharmaceuticals, Inc; Merck Sharp & Dohme LLC
Recruiting
-
Posted: June 1st, 2021, 2:00pm GMT
Condition: Advanced Solid Tumours
Interventions: Drug: RXC004; Biological: Denosumab
Sponsor: Redx Pharma Plc
Recruiting
-
Posted: June 1st, 2021, 2:00pm GMT
Conditions: Cancer Pain; Visceral Pain; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Small Intestine Cancer; Pancreas Cancer; Liver Cancer; Colon Cancer; Biliary Tract Cancer; Stomach Cancer; Rectum Cancer; Peritoneal Cancer; Gastrointestinal Cancer Metastatic; Gastrointestinal Cancers - Anus; Gastrointestinal Cancers - Stomach; Gastrointestinal Cancers - Colorectal; Gastrointestinal Cancers - Small Intestine; Small Intestine Cancer Stage III; Small Intestine Cancer Stage IV; Small Intestine Cancer, Recurrent; Pancreas Cancer, Stage III; Pancreas Cancer, Stage IV; Pancreas Cancer, Metastatic; Pancreas Cancer, Recurrent; Liver Cancer Stage IIIa; Liver Cancer Stage IIIb; Liver Cancer Stage IIIc; Liver Cancer Stage IV; Colon Cancer Stage III; Colon Cancer Stage IV; Stomach Cancer Stage III; Stomach Cancer Stage IV; Stomach Cancer Recurrent; Rectum Cancer, Recurrent; Gastrointestinal Cancers - Liver; Anal Cancer; Anal Cancer Stage III; Anal Cancer Stage IV; Anal Cancer Recurrent; Anal Cancer Metastatic; Anal Cancer, Stage IIIA; Anal Cancer, Stage IIIB; Appendix Cancer; Ampullary Cancer; Bile Duct Cancer; Bile Duct Cancer Stage III; Bile Duct Cancer Stage IV; Bile Duct Cancer Stage IVA; Bile Duct Cancer Stage IVB; Bile Duct Cancer Recurrent; Carcinoid Tumor; Carcinoid Tumor of Pancreas; Carcinoid Tumor of Large Intestine; Carcinoid Tumor of GI System; Carcinoid Tumor of Colon; Carcinoid Tumor of Liver; Carcinoid Tumor of Cecum; Carcinoid Tumor of Ileum; Carcinoid Tumor of Rectum; Carcinoid Tumor of the Small Bowel; Carcinoid Tumor of the Stomach; Large Intestine Cancer; Esophagus Cancer; Esophagus Cancer, Stage III; Esophagus Cancer, Stage IV; Esophagus Cancer, Recurrent; Gallbladder Cancer; Gallbladder Cancer Stage III; Gallbladder Cancer Stage IV; Gastric (Stomach) Cancer; Neuroendocrine Tumor; Peritoneum Cancer; Rectal Cancer; Esophagus Cancer, Stage I; Esophagus Cancer, Stage II; Gallbladder Cancer Stage I; Gallbladder Cancer Stage II; Bile Duct Cancer Stage I; Bile Duct Cancer Stage II
Intervention: Device: PICO G2 4k
Sponsors: Cedars-Sinai Medical Center; National Cancer Institute (NCI)
Recruiting
-
Posted: May 20th, 2021, 2:00pm GMT
Conditions: HRD; Cholangiocarcinoma; Metastatic Cancer
Interventions: Drug: Niraparib; Drug: Dostarlimab
Sponsors: Walid Shaib, MD; Emory University; GlaxoSmithKline
Recruiting
-
Posted: May 18th, 2021, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Dexamethasone; Drug: Floxuridine (FUDR); Device: Implanted Medical Device
Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting
-
Posted: April 26th, 2021, 2:00pm GMT
Condition: Cholangiocarcinoma Non-resectable
Intervention: Drug: Hematoporphyrin
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting
-
Posted: March 23rd, 2021, 2:00pm GMT
Condition: Malignant Gastric Outlet Obstruction
Intervention: Procedure: EUS-guided gastroenterostomy
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting
-
Posted: March 12th, 2021, 3:00pm GMT
Condition: Solid Tumor
Interventions: Drug: IDE397; Drug: Docetaxel; Drug: Paclitaxel; Drug: Gemcitabine; Drug: Nab paclitaxel; Drug: Pemetrexed
Sponsor: IDEAYA Biosciences
Recruiting
-
Posted: March 11th, 2021, 3:00pm GMT
Conditions: Uveal Melanoma; Cutaneous Melanoma; BAP1 Gene Mutation; Renal Cell Carcinoma; Mesothelioma; Hepatocellular Carcinoma; Cholangiocarcinoma; Meningioma Atypical
Intervention:
Sponsor: Mohamed Abdel-Rahman
Recruiting
-
Posted: February 18th, 2021, 3:00pm GMT
Condition: Bile Duct Obstruction, Extrahepatic
Intervention: Diagnostic Test: Cytology staining
Sponsor: Gangnam Severance Hospital
Recruiting
-
Posted: February 8th, 2021, 3:00pm GMT
Conditions: Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Bladder Cancer; Small-cell Lung Cancer; Prostate Cancer; Thyroid Cancer; Sarcoma; Gastric Cancer; Gallbladder Cancer
Interventions: Drug: TT-00420; Combination Product: Nab-Paclitaxel
Sponsor: TransThera Sciences (Nanjing), Inc.
Recruiting
-
Posted: January 13th, 2021, 3:00pm GMT
Conditions: Locally Advanced Intrahepatic Cholangiocarcinoma; Metastatic Intrahepatic Cholangiocarcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8
Interventions: Drug: Bintrafusp Alfa; Procedure: Biopsy; Radiation: Hypofractionated Radiation Therapy
Sponsor: M.D. Anderson Cancer Center
Recruiting
-
Posted: December 28th, 2020, 3:00pm GMT
Conditions: Colorectal Cancer Metastatic to Liver; Intrahepatic Cholangiocarcinoma
Intervention: Device: Medtronic SynchroMed II programmable pump connected to an Intera tapered catheter (Combined Infusion System)
Sponsor: Ronald DeMatteo, M.D.
Recruiting
-
Posted: December 24th, 2020, 3:00pm GMT
Conditions: Solid Tumor; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma; Pancreatic Cancer; Biliary Tract Cancer; Cholangiocarcinoma; Metastatic Cancer
Interventions: Biological: BNT141; Drug: Nab-paclitaxel; Drug: Gemcitabine
Sponsor: BioNTech SE
Recruiting
-
Posted: December 21st, 2020, 3:00pm GMT
Conditions: Hepatocellular Carcinoma; Liver Metastases; Cholangiocarcinoma
Intervention: Drug: STP705
Sponsors: Sirnaomics; Translational Drug Development
Recruiting
-
Posted: December 17th, 2020, 3:00pm GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym024
Sponsor: Symphogen A/S
Recruiting
-
Posted: November 24th, 2020, 3:00pm GMT
Conditions: Metastatic Cancer; Solid Tumor
Interventions: Drug: Sym021; Drug: Sym022; Drug: Sym023; Drug: Irinotecan Hydrochloride
Sponsor: Symphogen A/S
Recruiting
-
Posted: September 28th, 2020, 2:00pm GMT
Conditions: Pancreatic Cancer; Small Bowel Cancer; Colorectal Cancer; Melanoma; Non Small Cell Lung Cancer; Thyroid Cancer; Bladder Cancer; Head and Neck Cancer; Gastric Cancer; Esophageal Cancer; Cholangiocarcinoma; Ovarian Cancer; Hepatocellular Carcinoma; Glioblastoma; MAPK Gene Mutation; KRAS Activating Mutation; BRAF Gene Mutation; NRAS Gene Mutation; HRAS Gene Mutation; MEK Mutation; ERK Mutation
Intervention: Drug: Ulixertinib (BVD-523)
Sponsors: xCures; Cancer Commons
Available
-
Posted: September 23rd, 2020, 2:00pm GMT
Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer; Intrahepatic Cholangiocarcinoma; Perihilar Cholangiocarcinoma; Extrahepatic Cholangiocarcinoma; Hilar Cholangiocarcinoma; Distal Bile Duct Cancer
Intervention: Diagnostic Test: Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
Sponsors: University of Washington; Natera, Inc.; SEngine Precision Medicine, Inc.
Recruiting
-
Posted: September 16th, 2020, 2:00pm GMT
Condition: Advanced Biliary Tract Carcinoma
Interventions: Drug: Pembrolizumab Injection [Keytruda]; Drug: Lenvatinib Mesylate
Sponsors: Shanghai Jiahui International Hospital; Shanghai Zhongshan Hospital
Recruiting
-
Posted: August 20th, 2020, 2:00pm GMT
Conditions: Cholangiocarcinoma; Chondrosarcoma; Glioma; Any Solid Tumor
Interventions: Drug: LY3410738; Drug: Gemcitabine; Drug: Cisplatin; Drug: Durvalumab
Sponsors: Eli Lilly and Company; Loxo Oncology, Inc.
Recruiting
-
Posted: August 11th, 2020, 2:00pm GMT
Condition: Advanced Cholangiocarcinoma
Intervention: Drug: TAS-120
Sponsor: Taiho Oncology, Inc.
Available
-
Posted: July 30th, 2020, 2:00pm GMT
Conditions: Advanced Bile Duct Carcinoma; Advanced Breast Carcinoma; Advanced Cervical Carcinoma; Advanced Endometrial Carcinoma; Advanced Esophageal Carcinoma; Advanced Gastric Carcinoma; Advanced Head and Neck Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Advanced Lung Small Cell Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Penile Carcinoma; Advanced Pleural Malignant Mesothelioma; Advanced Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage III Gastric Cancer AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Stage III Cervical Cancer AJCC v8; Stage III Distal Bile Duct Cancer AJCC v8; Stage III Intrahepatic Bile Duct Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Penile Cancer AJCC v8; Stage III Pleural Malignant Mesothelioma AJCC v8; Stage IV Cervical Cancer AJCC v8; Stage IV Distal Bile Duct Cancer AJCC v8; Stage IV Intrahepatic Bile Duct Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Penile Cancer AJCC v8; Stage IV Pleural Malignant Mesothelioma AJCC v8; Triple-Negative Breast Carcinoma; Unresectable Urothelial Carcinoma
Interventions: Drug: Cisplatin; Drug: Elimusertib; Drug: Gemcitabine Hydrochloride
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: July 23rd, 2020, 2:00pm GMT
Conditions: Hepatocellular Cancer; Cholangiocarcinoma; Gallbladder Cancer; Pancreatic Cancer; Oesophageal Cancer; Stomach Cancer
Intervention: Diagnostic Test: FoundationOne®CDx and FoundationOne®Liquid
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; Roche Pharma AG
Recruiting
-
Posted: July 10th, 2020, 2:00pm GMT
Condition: HER2-amplified Biliary Tract Cancers
Interventions: Drug: ZW25 (Zanidatamab); Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay; Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay
Sponsors: Zymeworks Inc.; BeiGene, Ltd.
Recruiting
-
Posted: July 7th, 2020, 2:00pm GMT
Conditions: Bladder Carcinoma; Cervical Carcinoma; Cholangiocarcinoma; Hematopoietic and Lymphoid Cell Neoplasm; Hepatocellular Carcinoma; Malignant Adrenal Gland Neoplasm; Malignant Brain Neoplasm; Malignant Pleural Neoplasm; Malignant Skin Neoplasm; Malignant Solid Neoplasm; Malignant Testicular Neoplasm; Malignant Thymus Neoplasm; Neuroendocrine Neoplasm; Thyroid Gland Carcinoma; Urothelial Carcinoma
Interventions: Procedure: Computed Tomography; Drug: Gallium Ga 68 FAPi-46; Procedure: Positron Emission Tomography
Sponsor: Jonsson Comprehensive Cancer Center
Recruiting
-
Posted: June 24th, 2020, 2:00pm GMT
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Liver Cancer; Precancerous Condition; Benign Hepatobiliary Disease; Healthy, no Evidence of Disease
Interventions: Other: Gene expression analysis; Other: Genomic analysis; Other: Protein expression analysis; Other: Proteomic profiling; Other: Polymerase chain reaction; Other: Mass spectrometry; Other: Immunohistochemistry; Other: Metabolomics profiling; Other: Methylation and epigenetic analysis; Other: Liquid biopsy analysis; Other: Laboratory biomarker analysis
Sponsors: Peking Union Medical College Hospital; OrigiMed; GeneCast Biotechnology Co., Ltd.; YuceBio Technology Co., Ltd.
Recruiting
-
Posted: June 12th, 2020, 2:00pm GMT
Conditions: Astrocytoma; Brain Cancer; Brain Metastases; Bladder Cancer; Breast Cancer; Cervical Cancer; Cholangiocarcinoma; Colorectal Cancer; Esophagus Cancer; Gastric Cancer; Head and Neck Cancer; Kidney Cancer; Liver Cancer; Lung Cancer; Melanoma; Ovarian Cancer; Pancreatic Cancer; Pleural Mesothelioma; Prostate Cancer; Sarcoma; Tongue Cancer; Thymic Carcinoma; Urinary Tract Cancer
Intervention: Drug: QBS10072S
Sponsors: Quadriga Biosciences, Inc.; Novotech (Australia) Pty Limited
Recruiting
-
Posted: June 9th, 2020, 2:00pm GMT
Conditions: Colorectal Cancer; Pancreatic Cancer; Gastric Cancers; Cholangiocarcinoma
Intervention: Drug: BOLD-100 in combination with FOLFOX Chemotherapy
Sponsor: Bold Therapeutics, Inc.
Recruiting
-
Posted: June 1st, 2020, 2:00pm GMT
Condition: Metastatic and Locally Advanced NRG1-rearranged Malignancies
Intervention: Drug: Afatinib 40 MG
Sponsors: German Cancer Research Center; German Consortium for Translational Cancer Research
Recruiting
-
Posted: May 22nd, 2020, 2:00pm GMT
Conditions: Pancreatic Adenocarcinoma; Pancreatic Cysts; Pancreatic Endocrine Tumors; Chronic Pancreatitis; Cholangiocarcinoma, Extrahepatic; Ampullary Adenocarcinoma; Duodenal Adenocarcinoma
Interventions: Procedure: Robotic pancreaticoduodenectomy; Procedure: Open pancreaticoduodenectomy
Sponsors: Ruijin Hospital; Intuitive Surgical
Recruiting
-
Posted: May 7th, 2020, 2:00pm GMT
Condition: Unresectable Cholangiocarcinoma
Interventions: Drug: Neoadjuvant Chemo-radiotherapy; Procedure: Liver Transplantation
Sponsor: Hospital Vall d'Hebron
Recruiting
-
Posted: April 27th, 2020, 2:00pm GMT
Condition: Gallbladder Cancer
Interventions: Combination Product: Shortened hydration time and dispensary of Akynzeo; Combination Product: Standard of care
Sponsors: Imperial College Healthcare NHS Trust; Chugai Pharma UK Limited
Recruiting
-
Posted: March 16th, 2020, 2:00pm GMT
Conditions: Primary Sclerosing Cholangitis; Cholestasis
Interventions: Drug: Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy; Drug: Placebo of Bezafibrate in addition to standard UDCA therapy
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting
-
Posted: February 5th, 2020, 3:00pm GMT
Conditions: Liver and Intrahepatic Bile Duct Carcinoma; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Drug: Dexamethasone; Drug: Floxuridine; Device: Implanted Medical Device; Drug: Irinotecan; Drug: Leucovorin; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsors: OHSU Knight Cancer Institute; Oregon Health and Science University
Recruiting
-
Posted: January 23rd, 2020, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Durvalumab; Drug: Tremelimumab
Sponsors: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest; AstraZeneca
Recruiting
-
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Recruiting
-
Posted: December 6th, 2019, 3:00pm GMT
Conditions: Advanced or Metastatic Solid Tumor; Advanced or Metastatic Gastric or Gastroesophageal Cancer; Myeloid or Lymphoid Neoplasms (MLN)
Intervention: Drug: Futibatinib
Sponsor: Taiho Oncology, Inc.
Recruiting
-
Posted: November 15th, 2019, 3:00pm GMT
Conditions: Advanced Colorectal Carcinoma; Metastatic Colorectal Carcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8; Stage II Colon Cancer; Stage II Rectal Cancer; Stage III Colon Cancer; Stage III Rectal Cancer; Esophageal Cancer; Pancreatic Cancer; Bile Duct Cancer; Gastric Cancer; Gall Bladder Cancer; Small Bowel Adenocarcinoma
Interventions: Biological: Bevacizumab; Drug: Dasatinib; Drug: Fluorouracil; Drug: Leucovorin; Drug: Leucovorin Calcium; Drug: Oxaliplatin; Other: Quality-of-Life Assessment
Sponsor: Anne Noonan
Recruiting
-
Posted: November 8th, 2019, 3:00pm GMT
Conditions: Advanced Solid Tumors; NSCLC; Bladder Cancer; HNSCC; Renal Cancer; Melanoma; Anal Cancer; Colorectal Cancer; Cholangiocarcinoma; Gastric Cancer; Hepatocellular Carcinoma; Merkel Cell Carcinoma; Cervical Cancer
Interventions: Drug: Continue PD-1/PD-L1 Inhibitors treatment; Other: Discontinue PD-1/PD-L1-1 inhibitor
Sponsor: Antoinette J Wozniak, MD
Recruiting
-
Posted: October 21st, 2019, 2:00pm GMT
Condition: Primary Sclerosing Cholangitis
Interventions: Drug: Simvastatin 40mg; Drug: Placebo oral tablet
Sponsor: Annika Bergquist
Recruiting
-
Posted: September 18th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; FGFR2 Gene Rearrangements
Interventions: Drug: TAS-120; Drug: Cisplatin/Gemcitabine
Sponsor: Taiho Oncology, Inc.
Recruiting
-
Posted: September 12th, 2019, 2:00pm GMT
Conditions: Advanced Cholangiocarcinoma; Metastatic Cholangiocarcinoma; Unresectable Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Ivosidenib; Drug: Pemigatinib
Sponsors: Academic and Community Cancer Research United; National Cancer Institute (NCI)
Recruiting
-
Posted: September 12th, 2019, 2:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: derazantinib
Sponsor: Basilea Pharmaceutica
Available
-
Posted: July 30th, 2019, 2:00pm GMT
Conditions: Cholangiocarcinoma; Choledocholithiasis; Cholangitis; Pancreatic Cancer; Pancreatitis
Interventions: Procedure: Fistulotomy - High experienced.; Procedure: Fistulotomy - Low experienced.; Procedure: Conventional (guidewire) cannulation- High experienced; Procedure: Conventional (guidewire) cannulation - Low experienced
Sponsor: Coordinación de Investigación en Salud, Mexico
Recruiting
-
Posted: May 8th, 2019, 2:00pm GMT
Conditions: Stage III Hepatocellular Carcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Hepatocellular Carcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8; Stage IV Hepatocellular Carcinoma AJCC v8; Stage IV Intrahepatic Cholangiocarcinoma AJCC v8; Stage IVA Hepatocellular Carcinoma AJCC v8; Stage IVB Hepatocellular Carcinoma AJCC v8; Unresectable Hepatocellular Carcinoma; Unresectable Intrahepatic Cholangiocarcinoma
Interventions: Radiation: External Beam Radiation Therapy; Biological: Pneumococcal 13-valent Conjugate Vaccine; Biological: Therapeutic Autologous Dendritic Cells
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting
-
Posted: April 29th, 2019, 2:00pm GMT
Condition: HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Interventions: Drug: ZW25 (Zanidatamab); Drug: Capecitabine; Drug: Cisplatin; Drug: Fluorouracil; Drug: Leucovorin; Drug: Oxaliplatin; Drug: Bevacizumab; Drug: Gemcitabine
Sponsor: Zymeworks Inc.
Recruiting
-
Posted: April 9th, 2019, 2:00pm GMT
Conditions: Mesothelioma; Mesothelioma, Malignant; Mesothelioma; Pleura; Mesotheliomas Pleural; Mesothelioma Peritoneum; Cholangiocarcinoma; Cholangiocarcinoma Recurrent; Ovarian Cancer; Non Small Cell Lung Cancer; Non Small Cell Lung Cancer Metastatic; High Grade Ovarian Serous Adenocarcinoma
Interventions: Biological: gavo-cel; Drug: fludarabine; Drug: cyclophosphamide; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: TCR2 Therapeutics; Bristol-Myers Squibb
Recruiting
-
Posted: March 18th, 2019, 2:00pm GMT
Conditions: Malignant Solid Neoplasm; Refractory Cholangiocarcinoma; Refractory Malignant Solid Neoplasm
Interventions: Drug: Ceralasertib; Drug: Olaparib
Sponsor: National Cancer Institute (NCI)
Recruiting
-
Posted: January 29th, 2019, 3:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Biological: autologous Tcm cellular immunotherapy
Sponsors: Newish Technology (Beijing) Co., Ltd.; Peking Union Medical College Hospital
Recruiting